REGENERON PHARMACEUTICALS, INC. (REGN) Cash flow statement
Top 10 of 23 line items reported by REGN · 250+ in the full API →
REGENERON PHARMACEUTICALS, INC. (REGN) · Cash Flow Statement
Consolidated Statements of Cash Flows
Annual · In millions USD, except per-share data · Latest filed Feb 4, 2026 · FY ends Dec 31
| Fiscal Years Ended | |||||
|---|---|---|---|---|---|
FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 | Trend | |
| Net Cash Flow from Operating Activities | $4,978.9 | $4,420.5 | $4,594 | $5,014.9 | |
| Net Income | 4,504.9 | 4,412.6 | 3,953.6 | 4,338.4 | |
| Net Cash Flow from Investing Activities | $(629.1) | $(2,468.1) | $(3,185.1) | $(3,784.6) | |
| Capital Expenditures | -898.4 | -755.9 | -718.6 | -590.1 | |
| Net Cash Flow from Financing Activities | $(3,715.4) | $(2,200.5) | $(1,790.1) | $(1,009) | |
| Common stock issued | 635.9 | 1,465.3 | 1,145.5 | 1,519.5 | |
| Common stock repurchased | -3,438.6 | -2,603.3 | -2,235 | -2,082.8 | |
| Other financing activities | (10.3) | (33.4) | 0 | 0 | |
| Net Cash Flow | $634.7 | $(248.8) | $(381.6) | $221.3 | |
| Free Cash Flow | 4,080.5 | 3,664.6 | 3,875.4 | 4,424.8 | |
13 more line items available via the API
Depreciation & AmortizationStock-Based CompensationAccounts receivableInventoriesOther current assetsAccounts payableNet Debt Issued (Repaid)Total debt issuedShort-term debt issuedLong-term debt issuedTotal debt repaidShort-term debt repaidLong-term debt repaid